Can schizophrenia and ASPD be comorbid

Psychotic disorders and comorbid addictions

  • 1.

    Baker AL, Thornton LK, Hides L, Dunlop A (2012) Treatment of cannabis use among people with psychotic disorders: a critical review of randomized controlled trials. Curr Pharm Des 18: 4923-4937

    CASArticle Google Scholar

  • 2.

    Barrowclough C, Haddock G, Wykes T et al (2010) Integrated motivational interviewing and cognitive behavioral therapy for people with psychosis and comorbid substance misuse: randomized controlled trial. BMJ 341: c6325

    Article Google Scholar

  • 3.

    Bechdolf A, Pohlmann B, Güttgemanns J, Geyer C, Lindner K, Ferber C, Gouzoulis-Mayfrank E (2012) Stage-dependent motivational treatment in patients with the double diagnosis of psychosis and addiction: results of a randomized study. Neurologist 83: 888-896

    CASArticle Google Scholar

  • 4.

    Bennett ME, Bellack AS, Gearon JS (2001) Treating substance abuse in schizophrenia. An initial report. J Subst Abuse Treat 20: 163-175

    CASArticle Google Scholar

  • 5.

    Blanchard JJ, Brown SA, Horan WP, Sherwood AR (2000) Substance use disorders in schizophrenia: review, integration, and a proposed model. Clin Psychol Rev 20: 207-234

    CASArticle Google Scholar

  • 6.

    Brunette MF, Dawson R, O’Keefe CD et al (2011) A randomized trial of clozapine versus other antipsychotics for cannabis use disorder in patients with schizophrenia. J Dual Diagn 7: 50-63

    Article Google Scholar

  • 7.

    Chambers RA, Krystal JH, Self DW (2001) A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry 50: 71-83

    CASArticle Google Scholar

  • 8.

    Cleary M, Hunt GE, Matheson SL, Siegfried N, Walter G (2010) Psychosocial interventions for people with both severe mental illness and substance misuse. The Cochrane Collaboration. Editorial Group: Cochrane Schizophrenia Group. John Wiley & Sons Ltd

  • 9.

    D’Amelio R, Behrendt BWT (2007) Psychoeducation, Schizophrenia and Addiction. Manual for leading patient and family groups. Elsevier / Urban & Fischer, Munich

    Google Scholar

  • 10.

    Dixon L (1999) Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr Res 35 (Suppl): S93-S100

    Article Google Scholar

  • 11.

    DGPPN (Ed) (2006) S3 Practice Guidelines in Psychiatry and Psychotherapy. Volume 1 - Schizophrenia Treatment Guideline. Steinkopff-Verlag, Darmstadt, S 225-227

    Google Scholar

  • 12.

    Drake RE, Mueser KT (2000) Psychosocial approaches to dual diagnosis. Schizophr Bull 26: 105-118

    CASArticle Google Scholar

  • 13.

    Drake RE, Mercer-McFadden C, Mueser KT, McHugo GJ, Bond GR (1998) Review of integrated mental health and substance abuse treatment for patients with dual disorders. Schizophr Bull 24: 589-608

    CASArticle Google Scholar

  • 14.

    Drake RE, Mueser KT, Brunette MF, McHugo GJ (2004) A review of treatments for people with severe mental illnesses and co-occurring substance use disorders. Psychiatric Rehabil J 27: 360–374

    Article Google Scholar

  • 15.

    Drake RE, O'Neal EL, Wallach MA (2008) A systematic review of psychosocial research on psychosocial interventions for people with co-occurring severe mental and substance use disorders. J Subst Abuse Treat 34: 123-138

    Article Google Scholar

  • 16.

    Gouzoulis-Mayfrank E (2007) Comorbidity Psychosis and Addiction - Basics and Practice - With manuals for psychoeducation and behavior therapy, 2nd expanded edition with the collaboration of Schnell T. Steinkopff, Darmstadt

    Google Scholar

  • 17.

    Gouzoulis-Mayfrank E (2014) Psychotic disorders and comorbid addictions. In: Walter M, Gouzoulis-Mayfrank E (eds). Mental disorders and addictions - diagnosis and treatment of double diagnoses. Kohlhammer, Stuttgart, pp. 75-87

    Google Scholar

  • 18.

    Gouzoulis-Mayfrank E, König S, Koebke S, Schnell T, Schmitz-Buhl M, Daumann J (2015) Trans-sector integrated treatment in psychosis and addiction. A randomized controlled study of a motivational, cognitive behavioral therapy program under standard hospital treatment conditions. Dtsch Arztebl Int 112: 683-691

    PubMedPubMed Central Google Scholar

  • 19.

    Green AI (2005) Schizophrenia and comorbid substance use disorder: effects of antipsychotics. J Clin Psychiatry 66 (Suppl 6): 21-26

    PubMed Google Scholar

  • 20.

    Hjorthoj CR, Fohlmann A, Larsen AM, Gluud C, Arendt M, Nordentoft M (2013) Specialized psychosocial treatment plus treatment as usual (TAU) versus TAU for patients with cannabis use disorder and psychosis: the CapOpus randomized trial. Psychol Med 43: 1499-1510

    CASArticle Google Scholar

  • 21.

    Hufnagel S (2015) Development, implementation and evaluation of group psychotherapy for forensically accommodated patients with the comorbidity of schizophrenia and addiction (according to ICD-10): The forensic double diagnosis group. Inaugural dissertation to obtain the title of doctor rerum medicinalium of the High Medical Faculty of the University of Cologne. http://digitool.hbz-nrw.de:1801/webclient/StreamGate?folder_id=0&dvs=1449174216387~860, last accessed on December 04, 2015

  • 22.

    Hunt GE, Siegfried N, Morley K, Sitharthan T, Cleary M (2013) Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database Syst Rev 10: CD001088

    Google Scholar

  • 23.

    Kutscher S, Schiffer B, Seifert D (2009) Schizophrenic patients in psychiatric measures (§ 63 StGB) North Rhine-Westphalia - developments and patient characteristics. Fortschr Neurol Psychiatr 77: 91-96

    CASArticle Google Scholar

  • 24.

    Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G (2007) Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370: 319-328

    Article Google Scholar

  • 25.

    Moran P, Hodgins S (2004) The correlates of comorbid antisocial personality disorder in schizophrenia. Schizophr Bull 30: 791-802

    Article Google Scholar

  • 26.

    Mueser KT, Fox L (2002) A family intervention program for dual disorders. Community Ment Health J 38: 253-270

    Article Google Scholar

  • 27.

    Mueser KT, Crocker AG, Frisman LB, Drake RE, Covell NH, Essock SM (2006) Conduct disorder and antisocial personality disorder in persons with severe psychiatric and substance use disorders. Schizophr Bull 32: 626-636

    Article Google Scholar

  • 28.

    Mueser KT, Drake RE, Wallach MA (1998) Dual diagnosis: a review of etiological theories. Addict Behav 23: 717-734

    CASArticle Google Scholar

  • 29.

    Mueser KT, Yarnold PR, Rosenberg SD, Swett C Jr, Miles KM, Hill D (2000) Substance use disorder in hospitalized severely mentally ill psychiatric patients: prevalence, correlates, and subgroups. Schizophr Bull 26: 179-192

    CASArticle Google Scholar

  • 30.

    Petrakis IL, O’Malley S, Rounsaville B, Poling J, Hugh-Strong C, Krystal JH (2004) Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology (Berl) 172: 291-297

    CASArticle Google Scholar

  • 31.

    Petrakis IL, Poling J, Levinson C, Nich C, Carroll K, Rounsaville B (2005) Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders. Biol Psychiatry 57: 1128-1137

    CASArticle Google Scholar

  • 32.

    Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK (1990) Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 264: 2511-2518

    CASArticle Google Scholar

  • 33.

    Rohdich R, Kirste A (2005) An integrated treatment approach for schizophrenic patients with addictions and personality disorders in the Clinic for Forensic Psychiatry Haina. Law Psychiatric 23: 116–122

    Google Scholar

  • 34.

    Rubio G, Martínez I, Ponce G, Jiménez-Arriero MA, López-Muñoz F, Alamo C (2006) Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatry 51: 531-539

    Article Google Scholar

  • 35.

    Sayers SL, Campbell EC, Kondrich J, Mann SC, Cornish J, O’Brien C, Caroff SN (2005) Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. J Nerv Ment Dis 193: 379-386

    Article Google Scholar

  • 36.

    Schnell T, Neisius K, Daumann J, Gouzoulis-Mayfrank E (2010) Prevalence of the comorbidity psychosis and addiction - clinical-epidemiological results from a German city. Neurologist 81: 323-328

    CASArticle Google Scholar

  • 37.

    Schnell T, Koethe D, Krasnianski A, Gairing S, Schnell K, Daumann J, Gouzoulis-Mayfrank E (2014) Ziprasidone vs. Clozapine in the treatment of dually diagnosed (DD) patients with schizophrenia and cannabis use disorders: a randomized study. Am J Addict 23: 308-312

    Article Google Scholar

  • 38.

    Stuyt EB, Sajbel TA, Allen MH (2006) Differing effects of antipsychotic medications on substance abuse treatment patients with co-occurring psychotic and substance abuse disorders. Am J Addict 15: 166-173

    Article Google Scholar

  • 39.

    Ziedonis DM, D’Avanzo K (1998) Schizophrenia and Substance abuse. In: Kranzler HR, Rounsaville BJ (eds). Dual diagnosis and treatment. Marcel Dekker, New York, pp. 427-465

    Google Scholar